Candidate drugs for maintenance therapy in CLL
| Drug . | Characteristics . | Current status in CLL . | Clinical trials in CLL: maintenance or consolidation . |
|---|---|---|---|
| Rituximab | Anti-CD20 mAb | Approved for previously untreated and refractory/relapsed patients | Several phase 2 clinical trials completed; no results of phase 3 randomized trial available |
| Alemtuzumab | Anti-CD52 mAb | Approved for previously untreated and refractory/relapsed patients | Several phase 2 clinical trials completed; phase 3 clinical trial stopped prematurely due to severe infections |
| Lenalidomide | Immunomodulator | Not approved to treat CLL | Phase 2 clinical trials completed; phase 3 clinical trial ongoing |
| Ibrutinib | Btk inhibitor | Not approved yet | Phase 2 and 3 clinical trials ongoing |
| Idelalisib | PI3Kδ inhibitor | Not approved yet | Phase 2 and 3 clinical trials ongoing |
| Drug . | Characteristics . | Current status in CLL . | Clinical trials in CLL: maintenance or consolidation . |
|---|---|---|---|
| Rituximab | Anti-CD20 mAb | Approved for previously untreated and refractory/relapsed patients | Several phase 2 clinical trials completed; no results of phase 3 randomized trial available |
| Alemtuzumab | Anti-CD52 mAb | Approved for previously untreated and refractory/relapsed patients | Several phase 2 clinical trials completed; phase 3 clinical trial stopped prematurely due to severe infections |
| Lenalidomide | Immunomodulator | Not approved to treat CLL | Phase 2 clinical trials completed; phase 3 clinical trial ongoing |
| Ibrutinib | Btk inhibitor | Not approved yet | Phase 2 and 3 clinical trials ongoing |
| Idelalisib | PI3Kδ inhibitor | Not approved yet | Phase 2 and 3 clinical trials ongoing |
Btk, Bruton tyrosine kinase; mAb, monoclonal antibody; PI3Kδ, phosphatidylinositol 3-kinase δ.